Hong Kong Island, Hong Kong, China Advantech Capital is the famous VC, which was founded in 2015.
The current fund was established by Jianming Yu. We also calculated 3 valuable employees in our database.
We can highlight the next thriving fund investment areas, such as Information Technology, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight SenseTime, Zhihu, Qutoutiao. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low.
The fund is generally included in 2-6 deals every year. Opposing the other organizations, this Advantech Capital works on 12 percentage points less the average amount of lead investments. Deals in the range of more than 100 millions dollars are the general things for fund. Speaking about the real fund results, this VC is 41 percentage points more often commits exit comparing to other organizations. The increased amount of exits for fund were in 2019. The typical startup value when the investment from Advantech Capital is more than 1 billion dollars. The top activity for fund was in 2018.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Advantech Capital, startups are often financed by Qiming Venture Partners, IDG Capital, Tencent Holdings. The meaningful sponsors for the fund in investment in the same round are Tencent Holdings, Qiming Venture Partners, OrbiMed. In the next rounds fund is usually obtained by Temasek Holdings, Legend Capital, Alibaba Group.
Related Funds
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
ELITE Technology | 11 Mar 2022 | Haidian District, Beijing, China | |||
CureGenetics | $60M | 05 Jan 2022 | Gusu District, Jiangsu, China | ||
Innoforce Pharmaceuticals | $57M | 06 Dec 2021 | Hangzhou, Zhejiang, China | ||
Ablaze Pharmaceuticals | $75M | 29 Nov 2021 | Jingan, Shanghai, China | ||
Zhimeng Biopharma | $54M | 08 Nov 2021 | Zhangdian District, Shandong, China | ||
Boan Biotech | $18M | 01 Oct 2021 | Yantai, Liaoning, China | ||
Onconano Medicine | $50M | 17 Jun 2021 | Dallas, Texas, United States | ||
Boan Biotech | $105M | 01 Jan 2021 | Yantai, Liaoning, China | ||
Harbour Biomed | $75M | 12 Mar 2020 | Shanghai, China |
– OncoNano Medicine, Inc. announced the raise of an approximate $50m Series B financing led by the healthcare investment team at Advantech Capital, a China-based cross border institutional investment fund.
– Proceeds of the financing will be used, in part, to support the Phase 3 clinical trials in the U.S. and Europe for pegsitacianine, an innovative real-time imaging agent used in intraoperative surgical resection of solid tumors, and accelerate the advancement of the company’s first therapeutic development program, ONM-501, a novel immune-therapeutic formulated with the company’s core delivery technology.
– OncoNano is focused on developing and commercializing innovative therapeutics and imaging agents using its proprietary NanoPEGylation™ technology platform.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
ELITE Technology | 11 Mar 2022 | Haidian District, Beijing, China | |||
CureGenetics | $60M | 05 Jan 2022 | Gusu District, Jiangsu, China | ||
Innoforce Pharmaceuticals | $57M | 06 Dec 2021 | Hangzhou, Zhejiang, China | ||
Ablaze Pharmaceuticals | $75M | 29 Nov 2021 | Jingan, Shanghai, China | ||
Zhimeng Biopharma | $54M | 08 Nov 2021 | Zhangdian District, Shandong, China | ||
Boan Biotech | $18M | 01 Oct 2021 | Yantai, Liaoning, China | ||
Onconano Medicine | $50M | 17 Jun 2021 | Dallas, Texas, United States | ||
Boan Biotech | $105M | 01 Jan 2021 | Yantai, Liaoning, China | ||
Harbour Biomed | $75M | 12 Mar 2020 | Shanghai, China |
